Solifenacin versus Tamsulosin for Double-J Stent-Related Symptoms: A Prospective Randomized Comparative Study

Abstract

Introduction: The purpose of this study is to assess the effectiveness of alpha blockers or anticholinergic in treating symptoms associated with DJ  stents.

Materials and Methods: A total of fifty-six symptomatic patients were included, and they were divided into groups A and B. Group A received  0.4 mg of tamsulosin, while Group B received 5 mg of solifenacin daily.  Patients were assessed for International Prostate Symptom Score (IPSS) and assessed to determine changes in symptom scores. SPSS version 25.0 was used for data analysis. 

Results: In Group A, the mean baseline IPSS was 18.25±3.42, whereas  Group B had 18.11± 3.38 (p = 0.87) with an effect size (Cohen’s d) of 0.04. In the final follow-up, Group A had a mean IPSS score of 10.22±2.71, whereas  Group B had 8.93± 2.65 (p = 0.021) with an effect size (Cohen’s d) of 0.48.  The mean baseline VAPS scores were in group A 6.78 ± 1.64, group B  6.14±1.68 (p=0.16), with effect size (Cohen’s d) 0.38. At the final follow-up,  Group A had 4.20±1.20, compared to 2.98±1.46 in Group B (p = 0.017), with  an effect size (Cohen’s d) of 0.89.

Conclusion: Solifenacin was associated with greater improvement in  reducing symptoms and improving overall quality of life.